Doc, what would you attribute to the reasoning for lack of refills being dispensed? Thanks
Just curious because you said "The company is not doing anything even after the panel meeting (surprisingly)." That's just not true. They just attended an investors conference where i would say by the applause people where listening. I have listened in the past on these live events where the room sounded empty. They are continuing work both here in the U.S. as well as overseas. They are busy I assure you and while they wait they are preparing to get this rolled out shortly after approval. Maybe even in talks with someone already about a partnership deal or better. Who knows!!!!
So what would you be saying or doing differently if you where them?
Other than calling people crybabies it's hard to argue with this post. Some may not like Ade for what might seem like lofty projections. His estimates and projections are his which he is entitled too.
I have yet to get back into Arena but found this while doing some research on ETRM.
"Australian researchers have found new weight loss drug Qsymia effective in maintaining or reducing weight, but hard for many patients to tolerate!"
I agree with you it seems a little ridiculous that it's not UP coming off what was an overwhelmingly positive recommendation. I also find it hard to believe ETRM was unnoticed in a market where obesity is front & center stage. If word was not getting out before it is now "I'm seeing it with my own two eyes!"
I think a 100+% gain as you suggested although maybe not what you hoped for is what we can expect on or shortly after approval. I am basing this on nothing more then what we already know from three other companies in the space. I said before, I think we can expect a market cap $300M-$500M as fair value considering this is what the market has suggested. We really have nothing else to base it off of. All three are early stage company/s (Arena-Vivus-Orex) with a play on the obesity space. Mind you two of those companies where once valued at $2B dollars before even hitting the market.
Good news is If approved I believe ETRM gets bought out or signs a partnership deal for ROW minus USA keeping it to themselves. If someone wants all of it they'll have to pay! But what's a $1B to a large company who gets a device with Billions in potential return!? They are BRILLIANTLY setting themselves up for a takeover by someone for the use of Safe & effective device for WW use.
I really do consider it a gift at these levels
We could be closer than we think. I know some disagree but I find it interesting EnteroMedics is already in discussions with the FDA surrounding the label. That's more info then what some other company/s divulge.
Nice find even posted today.
Nice summary. I also get the feeling their looking for some kind of deal for outside the U.S. keeping the U.S. in house. They won't be able to hold this down much longer imo. Approval is almost certain from everything I read and heard.
The real YMB poster JD has suggested R. Woods should be next in line as well. If he's not they should be looking outside the company for someone who is respected with a proven track record. Jack has a good track record to date (minus the EU) which should fall more on Craig imo. But for some reason or another Jack is not respected by those in the investment community.
There are a few other problems though. Sales, freebies, lack of refills and cost for those who have no provider coverage which is why there is a low refill rate. They get the freebies and don't get the refill.
The International Neuromodulation Society selected members of the international scientific community to analyze scientific evidence for current and future innovations related to neurostimulation and to use clinical experience to fill in any gaps in information. The experts determined that currently approved neurostimulation techniques and technologies have expanded physicians’ ability to treat patients in a more effective and specific fashion. However, there are several additional promising technologies and potential applications for neurostimulation that could move this field forward and expand its applicability. For example, neurostimulation therapy may be able to help treat a number of nonpain states, including obesity, Alzheimer’s disease, obsessive compulsive disorder and addiction. This project was supported by the International Neuromodulation Society.
For the whole story fix the link.
You're probably right but at these basement prices they left themselves little room imo. The closer we get to a decision the more pressure the shorts will face as new buyers load up. GL
Maybe someone is expecting some good news from the Growth conference on Thursday, I'm not real sure what that would be but there always seems to be somebody in the know before the average Joe. I would like nothing more than to get out of this range sending the shorts running for the hills.
"Mark B. Knudson, President and Chief Executive Officer is scheduled to participate in the Canaccord Genuity 34th Annual Growth Conference. The event will be held on August 14, 2014 at 11:30 am Eastern Time at the InterContinental Hotel, Boston, MA"
Could be, but why even go as far as discussions if you're not going to approve it? What's Entero going to say, no we don't agree with this, this, and that? I don't think so but who really knows. I thought it was very encouraging snippet from the CC. GL
I wouldn't count out Eli Lilly if there where interested parties. They do have a history.
Down a bit still over 7M I thought we might see a bigger drop. Oh well time is running out so the more the merrier if approved of course. Sounds positive though if their already in label discussions. I don't think we where supposed to know that yet.
She was wrong for even suggesting "It could be" She has no bringing this issue to the boards. It is just morally wrong. But again if she is having troubles I wish her the best of luck.